High-risk human papillomavirus E7 proteins target PTPN14 for degradation

mBio

Volumn 7, Issue 5, 2016, Pages

  White, Elizabeth A ^a   Münger, Karl ^b   Howley, Peter M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 14; ONCOPROTEIN; PROTEIN E7; RETINOBLASTOMA PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CALMODULIN BINDING PROTEIN; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; PROTEASOME; PTPN14 PROTEIN, HUMAN; UBR4 PROTEIN, HUMAN;

ALPHAPAPILLOMAVIRUS; ARTICLE; BETAPAPILLOMAVIRUS; CELL IMMORTALIZATION; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; VIRUS CARCINOGENESIS; CHEMISTRY; FEMALE; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM; PATHOGENICITY; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS CELL TRANSFORMATION;

CALMODULIN-BINDING PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS E7 PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; PROTEOLYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84994432469     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01530-16     Document Type: Article

References (68)

1. Howley PM, Schiller JT, Lowy DR. 2013. Papillomaviruses, p 1662-1703. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527
3. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84. http://dx.doi.org/10.1016/j.virol.2005.04.002
4. Howley PM, Livingston DM. 2009. Small DNA tumor viruses: large contributors to biomedical sciences. Virology 384:256-259. http://dx.doi.org/10.1016/j.virol.2008.12.006
5. Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology 445:138-168. http://dx.doi.org/10.1016/j.virol.2013.04.013
6. Dyson N, Guida P, Münger K, Harlow E. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66:6893-6902
7. Dyson N, Howley PM, Münger K, Harlow E. 1989. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. http://dx.doi.org/10.1126/science.2537532
8. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:4099-4105
9. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S. 1997. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 8:1277-1286
10. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624
11. Gonzalez SL, Stremlau M, He X, Basile JR, Münger K. 2001. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75:7583-7591. http://dx.doi.org/10.1128/JVI.75.16.7583-7591.2001
12. Jones DL, Münger K. 1997. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71:2905-2912
13. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136. http://dx.doi.org/10.1016/0092-8674(90)90409-8
14. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79. http://dx.doi.org/10.1126/science.2157286
15. James CD, Roberts S. 2016. Viral interactions with PDZ domaincontaining proteins-an oncogenic trait? Pathogens 5:E8. http://dx.doi.org/10.3390/pathogens5010008
16. Duensing S, Münger K. 2002. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62:7075-7082
17. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-3910
18. Halbert CL, Demers GW, Galloway DA. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65:473-478
19. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421
20. Storey A, Osborn K, Crawford L. 1990. Co-transformation by human papillomavirus types 6 and 11. J Gen Virol 71:165-171. http://dx.doi.org/10.1099/0022-1317-71-1-165
21. Barbosa MS, Vass WC, Lowy DR, Schiller JT. 1991. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 65:292-298
22. Heck DV, Yee CL, Howley PM, Münger K. 1992. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442-4446. http://dx.doi.org/10.1073/pnas.89.10.4442
23. Helt AM, Galloway DA. 2001. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 75:6737-6747. http://dx.doi.org/10.1128/JVI.75.15.6737-6747.2001
24. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. 1992. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66:1329-1335
25. Phelps WC, Münger K, Yee CL, Barnes JA, Howley PM. 1992. Structurefunction analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-2427
26. Banks L, Edmonds C, Vousden KH. 1990. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 5:1383-1389
27. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Münger K. 2005. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sc i U S A 102:11492-11497. http://dx.doi.org/10.1073/pnas.0505337102
28. McIntyre MC, Frattini MG, Grossman SR, Laimins LA. 1993. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol 67:3142-3150
29. Shin MK, Sage J, Lambert PF. 2012. Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Cancer Res 72: 5418-5427. http://dx.doi.org/10.1158/0008-5472.CAN-12-2083
30. White EA, Howley PM. 2013. Proteomic approaches to the study of papillomavirus-host interactions. Virology 435:57-69. http://dx.doi.org/10.1016/j.virol.2012.09.046
31. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol 86:13174-13186. http://dx.doi.org/10.1128/JVI.02172-12
32. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Münger K, Harper JW, Howley PM. 2012. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sc i U S A 109:E260-E267. http://dx.doi.org/10.1073/pnas.1116776109
33. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill DE, Munger K, Marto JA, Quackenbush J, Roth FP. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487:491-495. http://dx.doi.org/10.1038/nature11288
34. Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833-846. http://dx.doi.org/10.1038/nrm2039
35. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304:1164-1166. http://dx.doi.org/10.1126/science.1096096
36. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404. http://dx.doi.org/10.1158/2159-8290.CD-12-0095
37. Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ, McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguin N, Ben Chaabene R, Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI. 2016. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 48:398-406. http://dx.doi.org/10.1038/ng.3525
38. Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. 2015. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet 47:872-877. http://dx.doi.org/10.1038/ng.3349
39. Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, Park JI, Chen J. 2012. PTPN14 is required for the density-dependent control of YAP1. Genes Dev 26:1959-1971. http://dx.doi.org/10.1101/gad.192955.112
40. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20:1436-1447. http://dx.doi.org/10.1128/MCB.20.4.1436-1447.2000
41. Demers GW, Espling E, Harry JB, Etscheid BG, Galloway DA. 1996. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 70: 6862-6869
42. DeMasi J, Huh KW, Nakatani Y, Münger K, Howley PM. 2005. Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci U S A 102:11486-11491. http://dx.doi.org/10.1073/pnas.0505322102
43. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505. http://dx.doi.org/10.1016/0092-8674(93)90384-3
44. DeMasi J, Chao MC, Kumar AS, Howley PM. 2007. Bovine papillomavirus E7 oncoprotein inhibits anoikis. J Virol 81:9419-9425. http://dx.doi.org/10.1128/JVI.00422-07
45. Ciccolini F, Di Pasquale G, Carlotti F, Crawford L, Tommasino M. 1994. Functional studies of E7 proteins from different HPV types. Oncogene 9:2633-2638
46. Ibaraki T, Satake M, Kurai N, Ichijo M, Ito Y. 1993. Transacting activities of the E7 genes of several types of human papillomavirus. Virus Genes 7:187-196. http://dx.doi.org/10.1007/BF01702398
47. Bohl J, Hull B, Vande Pol SB. 2001. Cooperative transformation and coexpression of bovine papillomavirus type 1 E5 and E7 proteins. J Virol 75:513-521. http://dx.doi.org/10.1128/JVI.75.1.513-521.2001
48. Neary K, DiMaio D. 1989. Open reading frames E6 and E7 of bovine papillomavirus type 1 are both required for full transformation of mouse C127 cells. J Virol 63:259-266
49. Sarver N, Rabson MS, Yang YC, Byrne JC, Howley PM. 1984. Localization and analysis of bovine papillomavirus type 1 transforming functions. J Virol 52:377-388
50. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K. 2007. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81: 9737-9747. http://dx.doi.org/10.1128/JVI.00881-07
51. White EA, Kramer RE, Hwang JH, Pores Fernando AT, Naetar N, Hahn WC, Roberts TM, Schaffhausen BS, Livingston DM, Howley PM. 2015. Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol 89:2857-2865. http://dx.doi.org/10.1128/JVI.03282-14
52. Schlegel R, Phelps WC, Zhang YL, Barbosa M. 1988. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J 7:3181-3187
53. Munger K, Jones DL. 2015. Human papillomavirus carcinogenesis: an identity crisis in the retinoblastoma tumor suppressor pathway. J Virol 89:4708-4711. http://dx.doi.org/10.1128/JVI.03486-14
54. Todorovic B, Nichols AC, Chitilian JM, Myers MP, Shepherd TG, Parsons SJ, Barrett JW, Banks L, Mymryk JS. 2014. The human papillomavirus E7 proteins associate with p190RhoGAP and alter its function. J Virol 88:3653-3663. http://dx.doi.org/10.1128/JVI.03263-13
55. Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, Wu L, Wang H, Han SX, Zhu Q. 2015. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6:5932-5946
56. Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F. 2015. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog 11:e1004712. http://dx.doi.org/10.1371/journal.ppat.1004712
57. Kong Q, Wang W, Li P. 2015. Regulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication. Int J Clin Exp Pathol 8:15808-15813
58. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM. 2008. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3:e2557. http://dx.doi.org/10.1371/journal.pone.0002557
59. Zheng ZM, Wang X. 2011. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 1809:668-677. http://dx.doi.org/10.1016/j.bbagrm.2011.05.005
60. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q. 2013. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 32: 2220-2229. http://dx.doi.org/10.1038/onc.2012.231
61. Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH, Zhang J. 2013. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 32:1266-1273. http://dx.doi.org/10.1038/onc.2012.147
62. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. 2012. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26:54-68. http://dx.doi.org/10.1101/gad.173435.111
63. Hansen CG, Moroishi T, Guan KL. 2015. YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol 25:499-513. http://dx.doi.org/10.1016/j.tcb.2015.05.002
64. Ramesh M, Krishnan N, Muthuswamy SK, Tonks NK. 2015. A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. J Biol Chem 290: 9646-9659. http://dx.doi.org/10.1074/jbc.M114.627968
65. White EA, Walther J, Javanbakht H, Howley PM. 2014. Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J Virol 88:8201-8212. http://dx.doi.org/10.1128/JVI.01197-14
66. Smith JA, White EA, Sowa ME, Powell ML, Ottinger M, Harper JW, Howley PM. 2010. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc Natl Acad Sc i U S A 107:3752-3757. http://dx.doi.org/10.1073/pnas.0914818107
67. Nakatani Y, Konishi H, Vassilev A, Kurooka H, Ishiguro K, Sawada J, Ikura T, Korsmeyer SJ, Qin J, Herlitz AM. 2005. p600, a unique protein required for membrane morphogenesis and cell survival. Proc Natl Acad Sci U S A 102:15093-15098. http://dx.doi.org/10.1073/pnas.0507458102
68. Martínez-Noël G, Galligan JT, Sowa ME, Arndt V, Overton TM, Harper JW, Howley PM. 2012. Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes. Mol Cell Biol 32:3095-3106. http://dx.doi.org/10.1128/MCB.00201-12.